Skip to content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer

BMC Gastroenterology201515:56

https://doi.org/10.1186/s12876-015-0281-7

  • Received: 4 December 2014
  • Accepted: 13 April 2015
  • Published:
Open Peer Review reports

Abstract

Background

Radioactive iodine (I-131) is routinely used for the treatment of differentiated thyroid cancer following surgery. Drug-induced liver injury (DILI) is a leading cause of acute liver failure. Here we reported a rare case of diffuse hepatic uptake (DHU) of radioactive iodine (I-131) induced hepatotoxicity in patient with I-131 ablation therapy after thyroidectomy.

Case presentation

A 57-year-old woman was admitted due to jaundice, itching and dark urine with abnormally elevated liver function. She has performed thyroidectomy followed by 100mci radioactive I-131 ablation therapy 21 days ago. The basic hepatic protection could not efficiently prevent disease progression. The patient was further treated with methylprednisolone, the bilirubin and alanin aminotransferase were finally lowered back to normal in the follow-up visit.

Conclusion

To the best of our knowledge, this is the rare description of DILI complications in thyroidectomy patient due to I-131 ablation therapy. The patient responds to glucocorticoid therapy well, but not basic hepatic protection treatment. Even though this is only a single case, it reminds physicians make DILI in early consideration when patient present liver injury after I-131 ablation therapy.

Keywords

  • Hepatotoxicity
  • Drug-induced liver injury
  • I-131
  • Thyroid cancer

Background

In recent years, it has become common to administer radioactive I-131 as part of the therapeutic strategies in patients with thyroid carcinoma following the surgical procedure of total or partial thyroidectomy [1]. Ideally, I131 treatment should only ablate residual micro/macroscopic tumor cells in the thyroid and/or distant metastasis but not affect healthy tissues in the body. However, the posttherapy scans frequently reveal diffuse I-131 uptake in the liver [2-5]. This does not represent metastases in the liver, which appear as discrete lesions. Drug-induced liver injury (DILI), the term that describes abnormalities in liver function tests related to medication intake, is a leading cause of acute liver failure [6]. However, whether the diffuse hepatic uptake of I-131 following I131 ablation therapy would induce DILI remains unclear in thyroid cancer patient with thyroidectomy.

Here we report a rare case of DILI complications in thyroidectomy patient due to I-131 ablation therapy. There are three reasons make our case particularly all the more worthy of attention. First, the radioactive I131 ablation is a routine therapy for thyroid cancer patient after thyroidectomy; Second, I-131 ablation therapy could present diffuse hepatic uptake; Third, DILI is the leading reason for acute liver failure; I131 induced DILI does not response to the basic hepatic protection.

Case presentation

A 57-year-old Chinese woman was admitted to our unit with a one-week history of jaundice, itching and dark urine. She denied history of liver disease, metabolic syndrome (obesity, diabetes, hypertension, dyslipidemia) and alcohol exposure. She has been diagnosed as thyroid cancer (papillary thyroid cancer) and performed total thyroidectomy 3 months ago. The patient was further treated with 100 mCi radioactive I-131 therapy 21 days ago (Emission Computed Tomography (ECT) image taken 5 days after I131 therapy was shown as Figure 1). Before starting I131 treatment, she had undergone ultrasonography of the liver and serum biochemical tests including liver chemistry, with all results being within the normal range.
Figure 1
Figure 1

Emission Computed Tomography (ECT) 5 days after I131 treatment. As shown, I131 were uptaken mainly in the thyroid bed, but also in the liver, stomach, oral and nasal cavity.

On examination she presented with skin scratching, yellowish discoloration of the skin and sclerae (eyes), no edema, ascites nor encephalopathy were presented. Laboratory tests were abnormal: elevated total bilirubin (TB) = 131.1 μmol/L (7 folds above the upper limit of normal); Direct bilirubin(DB) = 82.1 μmol/L (10 folds increased); alanin aminotransferase(ALT) = 370 μ/L (9 folds increased); Aspartateaminotransferase(AST) = 189 μ/L (4.5 folds increased); gamma-glutamyltransferase (GGT) = 275 μ/L (6 folds increased); alkalinephosphatase (ALP), serum albumin, total bile acid and international normalized ratio (INR) were normal. Viral hepatitis (HAV(Ab), HBV (Ag/Ab), HCV(Ab, RNA),HEV(Ab), EBV(Ab), CMV(Ab) and HSV(Ab)), autoimmune serologies (antinuclear antibodies, anti-smooth muscle antibody, anti-mitochondrial antibody/M2, anti-liver-kidney microsomal antibody, anti-liver cell plasma antibody, anti-soluble liver antigen/liver–pancreas antigen) and serum tumor markers (AFP, CEA, CA125, CA19-9, CA15-3, CA72-4, FER, FPSA, PSA, SCC, NSE) were negative. No coagulopathy were observed. Iron and copper status were normal. Abdominal ultrasound revealed chronic diffuse hepatopathy, decreased size of gallbladder without gallstones or sludge and thicken gallbladder wall. There is no pericholecystic fluid. The common bile duct has a normal caliber. Enhanced Magnetic Resonance Imaging (MRI) and Magnetic Resonance CholangioPancreatography (MRCP, Figure 2) were normal.
Figure 2
Figure 2

Enhanced Magnetic Resonance imaging(MRI) and Magnetic Resonance Cholangio Pancreatography (MRCP) of this patient were normal.

The patient was initially treated with basic hepatic protection for 40 days, including glutathione, magnesium isoglycyrrhizinate, essential Nutrition, transmetil, and/or tauroursodeoxycholic acid. The total bilirubin was not efficiently controlled and kept increasing to 223.9 μmol/L 40 days later, even though the level of AST and ALT were decreased. Liver biopsy was further performed and the results showed swollen hepacytes, predominant piecemeal necrosis within the lobules, obvious canalicular and hepatocellular cholestasis [7]. The portal inflammation, hepatocyte rosettes and fibrosis were not detected (Figure 3). On the basis of Roussel Uclaf Causality Assessment Method (RUCAM = 6 for this patient, shown as Table 1) [8], it indicates the patient is probable I-131 administration induced liver injury. Therefore, the patient was further treated with methylprednisolone (40 mg iv drip qd*14d followed by maintenance and step-down withdrawal of oral methylprednisolone), the TB and ALT/AST were finally lowered back to normal in the end of follow-up visit (Figures 4 and 5). Considering the safety and validity to easterners, 40 mg iv drip qd is the standard initial dose in our institution for cholestatic DILI patients, who are insensitive to basis hepatic protection. The maintenance time and gradual reduction regime depend on the response of patients. Usually, the initial dose will be hold for the first 2 weeks, and the dose will be reduced 10% every 1-2 weeks when TB level was effectively controlled.
Figure 3
Figure 3

The representative images for Liver biopsy (A) and electron endoscopy(B) of this patient.

Table 1

Causality assessment of this patient

Criteria

Score

1. Time to onset of the reaction Suggestive

2 (5 to 90 days from the beginning of the initial I-131 treatment)

2. Course of the reaction

0 (no information )

3. Risk factor for drug reaction

1 (age of patient ≥55 years)

4. Concomitant drugs

0 (None)

5. Non drug-related causes

2 (None)

6. Previous information on the drug

1 (Reaction published but unlabelled)

7. Response to readministration

0 (Not done)

Total

6

Figure 4
Figure 4

Line chart for the bilirubin level of this patient.

Figure 5
Figure 5

Line chart for the AST/ALT level of this patient.

Discussion

Drug-induced liver injury(DILI) refers to liver injury caused by drugs or chemical agents, which represents viral hepatitis-like symptoms, malaise, anorexia, nausea and vomiting, right upper quadrant abdominal pain, jaundice, acholic stools, and dark urine, as a special type of adverse drug reaction [6,9,10]. DILI is one of the leading causes of acute liver failure in U.S.A., accounting for around 13% cases of acute liver failure [11]. In China, DILI causes 10% cases of acute hepatitis and 12.2% in acute liver failure. Exploring the risk of these events poses a major challenge for drug safety.

The therapeutic value of I-131 ablation therapy after total thyroidectomy has been used as an important component in thyroid cancer management [12,13]. Based on what is known so far, acute complications due to I-131 ablation therapy include transient parotitis and thyroiditis; reported chronic complications are amenorrhea, pulmonary fibrosis, azoospermia, aplastic anemia, and leukemia. The ablation-therapeutic I-131 induced DILI reaction has not been included either in I-131 product label or well-known reports.

Even though the radioactive I-131 becomes mainly toxic to thyroid cells that accumulate iodine from bloodstream, it also could be biodistributed to whole body and other organs. In total thyroidectomy patient, the lower gastrointestinal tract, kidney, stomach, heart wall and liver have been demonstrated to absorb relatively high doses per unit of administered iodine activity [14]. In this case, the emission computed tomography (ECT) I131 whole body scan demonstrated uptake mainly in the thyroid bed, but also in the liver, stomach, oral and nasal cavity 5 days after radioiodine treatment (Figure 1). Besides the biodistribution of I-131 in thyroidectomy patient, the high dose of I-131 used for ablation therapy might also be one of the reasons leading to DILI. Individual dose of I-131 ranges from 2 to 4 mCi for diagnosis, and ranges from 5 to 10 mCi for hyperthyroidism. However, it ranges from 75 to 150 mCi for therapeutic ablation therapy, which is 15 times higher than treating benign thyroid diseases and 35 times higher than monitoring purpose. Navina et al have reported the hepatotoxicity after I-131 treatment for 5 to 10 mCi each time in patients with Grave’s disease [15], which warns us to pay more attention to the possibility of hepatotoxicity induced by therapeutic I-131 ablation therapy with much higher I-131 dose.

Conclusion

To our knowledge, there is rare description of DILI complications due to I-131 ablation therapy in thyroidectomy patient. The patient, who denies history of liver disease, presents typical cholestatic damage manifestation with short course of reaction to I-131 administration, and responds to glucocorticoid therapy well, but not basic hepatic protection treatment. This is only a case report from one patient data, but it holds the significance to reveal the possibility of ablation I-131 therapy induced liver injury. As an additional remarks, it reminds physicians make DILI in early consideration when patient present liver injury after I-131 ablation therapy.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is submitted to this journal.

Abbreviations

DILI: 

Drug-induced liver injury

DHU: 

Diffuse hepatic uptake

I-131: 

Radioactive iodine

ECT: 

Emission Computed Tomography

AST: 

Aspartateaminotransferase

ALT: 

Alanin aminotransferase

TB: 

Direct bilirubin

GGT: 

Gamma-glutamyltransferase

ALP: 

Alkalinephosphatase

INR: 

International normalized ratio

MRI: 

Enhanced Magnetic Resonance Imaging

MRCP: 

Magnetic Resonance Cholangio Pancreatography

RUCAM: 

Roussel Uclaf Causality Assessment Method

Declarations

Acknowledgments

Grant support: the National Natural Science Foundation of China (No. 81272656).

Funding

National Natural Science Foundation of China (No. 81272656; 81000160).

Authors’ Affiliations

(1)
Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

References

  1. Chung JK, Cheon GJ. Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology. Endocrinol Metab (Seoul). 2014;29(3):233–9.View ArticleGoogle Scholar
  2. Ferris HA, Williams G, Parker JA, Garber JR. Endocr Pract. Therapeutic implications of diffuse hepatic uptake following I-131 therapy fordifferentiated thyroid cancer. Endocr Pract. 2013;19(2):263–7.View ArticlePubMedGoogle Scholar
  3. Tatar FA, Morita E, Ituarte PH, Cavalieri RR, Duh QY, Price DC, et al. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients. World J Surg. 2001;25:718–22.View ArticlePubMedGoogle Scholar
  4. Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med. 1988;13:657–60.View ArticlePubMedGoogle Scholar
  5. Omür O, Akgün A, Ozcan Z, Sen C, Ozkiliç H. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans. Clin Nucl Med. 2009;34:11–4.View ArticlePubMedGoogle Scholar
  6. Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J. Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol. 2014;13(2):248–55.PubMedGoogle Scholar
  7. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931–9.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–30.View ArticlePubMedGoogle Scholar
  9. Davern TJ. Drug-induced liver disease. Clin Liver Dis. 2012;16:231–45.View ArticlePubMedGoogle Scholar
  10. Sprague D, Bambha K. Drug-induced liver injury due to varenicline: a case report. BMC Gastroenterol. 2012;12:65.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Suk KT, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol. 2012;18:249–57.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Pacilio M, Bianciardi L, Panichelli V, Argirò G, Cipriani C. Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements. Nucl Med Commun. 2005;26:623–31.View ArticlePubMedGoogle Scholar
  13. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:1381–91.View ArticlePubMedGoogle Scholar
  14. Changlai SP, Chang PJ, Chen CY. Biodistribution and dosimetry of (131) I in thyroidectomy patients using semiquantitative gamma-camera imaging. Cancer Biother Radiopharm. 2008;23:759–66.View ArticlePubMedGoogle Scholar
  15. Jhummon NP, Tohooloo B, Qu S. Iodine-131 induced hepatotoxicity in previously healthy patients with Grave’s disease. Thyroid Res. 2013;6:4.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Lin et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement